Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles

Vaccine

Volumn 29, Issue 43, 2011, Pages 7326-7334

  Hanumantha Rao, N ^a   Baji Babu, P ^a   Rajendra, L ^a   Sriraman, R ^a   Pang, Yuk Ying S ^b   Schiller, John T ^b   Srinivasan, V A ^a  

^a Indian Immunologicals Limited   (India)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cervical cancer; Prophylactic vaccine; Pseudovirus neutralization assay; Virus like particles; Yeast

Indexed keywords

CAPSID PROTEIN L1; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CODON; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAPILLOMAVIRUS INFECTION; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FOLDING; TRANSMISSION ELECTRON MICROSCOPY; VIRUS CHARACTERIZATION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; VIRUS PURIFICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CLONING, MOLECULAR; HEK293 CELLS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MICE; MICE, INBRED BALB C; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PICHIA; VACCINES, VIRUS-LIKE PARTICLE;

EID: 80053439774     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.071     Document Type: Article

References (37)

1. Human papillomavirus and related cancers in India 2010, WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre), Summary Report: 4-5.
2. Parkin D.M., Louie K.S., Clifford G. Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region. Vaccine 2008, S26:M1-M16.
3. IARC monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses 2007, vol. 90. IARC Press, Lyon, p. 179-327.
4. Burd E.M. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003, 16:1-17.
5. De Villier E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324:17-27.
6. Bosch F.X., de Sanjose S Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003, 31:3-13.
7. Sankaranarayanan R., Bhatla N., Gravitt P.E., Basu P., Esmy P.O., Ashrafunnessa K.S., et al. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine 2008, 26(Suppl. 12):43-52.
8. Bharadwaja M., Hussain S., Nasare V., Das B.C. HPV & HPV vaccination: issues in developing countries. Indian J Med Res 2009, 130:327-333.
9. Hakama M., Miller A.B., Day N.E. Screening for cancer of the uterine cervix IARC working group on cervical cancer screening 1986, IARC Lyon IARC Press, p. 133-44.
10. Sankaranarayanan R., Esmy P.O., Rajkumar R., Muwonge R., Swaminathan R., Shanthakumari S. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomized trial. Lancet 2007, 370:398-406.
11. Schiller J.T., Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004, 2(4):343-347.
12. Villa L.L. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine 2006, 24(Suppl. 1):S23-S28.
13. Kirnbauer R., Booy F., Chang N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89:12180-12184.
14. Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185(1):251-257.
15. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martinus C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow up from a randomized control trial. Lancet 2006, 367:1247-1255.
16. Schiller J.T., Castellsauge X., Villa L.L., Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like-particles vaccine clinical trial results. Vaccine 2008, 26:53-61.
17. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356(19):1928-1943.
18. Basu P., Chowdhury D. Cervical cancer screening & HPV vaccination: a comprehensive approach to cervical cancer control. Indian J Med Res 2009, 130:241-246.
19. Bimelt S., Sonnewald U., Galmbachar P., Willmitzer L., Muller M. Production of human papillomaviruses type 16 virus-like particles in transgenic plants. J Virol 2003, 77:9211-9220.
20. Varsani A., Williamson A.L., Rose R.C., Jaffer M., Rybicki E.P. Expression of human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi. Arch Virol 2003, 148:1771-1786.
21. Liu D.W., Zhang Y., Yu X.H., Jiang C., Chen Y., Wu Y., et al. Assembly and immunogenicity of human papillomavirus type 16 major capsid protein (HPV16 L1) in Pichia pastoris. Chem Res Chin Univ 2007, 23(2):200-203.
22. Bazan S.B., de Alencar Muniz Chaves A., Aires K.A., Cianciarullo A.M., Garcea R.L., Ho P.L. Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris. Arch Virol 2009, 154(10):1609-1617.
23. Patel M.C., Patkar K.K., Basu A., Mohandas K.M., Mukhopadhyaya R. Production of immunogenic human papillomavirus-16 major capsid protein derived virus like particles. Indian J Med Res 2009, 130:213-218.
24. Inglis S., Shaw A., Koenig S. HPV vaccines: commercial research & development. Vaccine 2006, 24(Suppl. 3):S99-S105.
25. Cook J.C., Joyce J.G., George H.A., Schultz L.D., Hurni W.M., Jansen K.U., et al. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expr Purif 1999, 17:477-484.
26. Zhou J., Sun X.Y., Davies H., Crawford L., Park D., Frazer I.H. Definition of linear antigenic regions of the HPV 16 L1 capsid protein using synthetic virion-like particles. Virology 1992, 189:592-599.
27. Nardelli-Haefliger D., Roden R.B., Benyacoub J., Sahli R., Kraehenbuhl J.P., Schiller J.T., et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997, 65(8):3328-3336.
28. Buck C.B., Pastrana D.V., Lowy D.R., Schiller J.T. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 2005, 119:445-462.
29. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996, 223:174-184.
30. Ferlay J., Bray F., Pisani P., Parkin D.M. Cancer incidence, mortality and prevalence worldwide 2004, IARC Press, Lyon, IARC Cancer Base No. 5. version 2.0.
31. Sankaranarayanan R. Overview of cervical cancer in the developing world FIGO 6th Annual report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95(Suppl. 1):S205-S210.
32. Sankaranarayanan R. HPV vaccination: the promise & problems. Indian J Med Res 2009, 130:322-326.
33. Padmanabhan S., Amin T., Sampat B., Cook-Deegan R., Chandrasekharan S. Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. Nat Biotechnol 2010, 28:671-678.
34. Cregg J.M., Cereghino J.I., Shi J., Higgins D.R. Recombinant protein expression in Pichia pastoris. Mol Biotechnol 2000, 16:23-52.
35. Hu Y., Zandi R., Anavitarte A., Knobler C.M., Gelbart W.M. Packaging of a polymer by a viral capsid: the interplay between polymer length and capsid size. Biophys J 2008, 94:1428-1436.
36. World Health Organization Expert Committee on Biological Standardization Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines 2006, WHO, Geneva. http://screening.iarc.fr/doc/WHO_vaccine_guidelines_2006.pdf.
37. ® over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 2011, 7(2):230-238.